Autoimmune hepatitis: From mechanisms to therapy

Area of Science:

• Hepatology
• Immunology
• Gastroenterology

Background:

• Autoimmune hepatitis (AIH) is a progressive liver disease with unknown etiology, involving genetic and environmental factors.
• Immune reactions against liver antigens, particularly defects in regulatory T-cells, drive autoimmune liver injury.
• Key features include female predominance, hypergammaglobulinemia, autoantibodies, and interface hepatitis on histology.

Purpose of the Study:

• To summarize the understanding of autoimmune hepatitis (AIH) pathophysiology, diagnosis, and management.
• To differentiate between AIH types based on serological profiles.
• To outline treatment strategies and outcomes for AIH patients.

Main Methods:

• Review of the clinical presentation, diagnostic criteria, and immunological mechanisms of AIH.
• Classification of AIH into Type 1 (ANA/ASMA positive) and Type 2 (LKM1 positive).
• Analysis of treatment responses, including standard immunosuppression and alternative agents, and outcomes of liver transplantation.

Main Results:

• AIH is characterized by specific autoantibodies (ANA, ASMA, LKM1) and histological findings.
• Immunosuppressive therapy, primarily steroids +/- azathioprine, achieves remission in approximately 80% of patients.
• Alternative treatments and liver transplantation are options for refractory cases or end-stage liver disease.

Conclusions:

• AIH is a treatable autoimmune liver disease where early immunosuppression is crucial for favorable outcomes.
• Understanding the serological types guides diagnosis and potentially treatment approaches.
• Liver transplantation offers excellent results for advanced disease, though recurrence is possible.